{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for penicillin root_references_url in Reference URL (approximate match)
Status:
Possibly Marketed Outside US
Source:
M016
(2024)
Source URL:
First approved in 2024
Source:
M016
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2024)
Source URL:
First approved in 2024
Source:
505G(a)(3)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
M006
(2024)
Source URL:
First approved in 2024
Source:
M006
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2024)
Source URL:
First approved in 2021
Source:
Varecell Intensive Liposome Serum by D&S Cosmedique Co.Ltd
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
The Zoeun Skin Eye Cream by Sturgeonbio Co.,Ltd.
(2024)
Source URL:
First approved in 2021
Source:
M020
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
M020
(2021)
Source URL:
First approved in 2019
Source:
Active Firming Serum by Jafra cosmetics International
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Menopur by Ferring Pharmaceuticals [Canada]
Source URL:
First approved in 2016
Source:
NADA141431
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2014)
Source URL:
First approved in 2014
Source:
21 CFR 352
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Active Firming Serum by Jafra cosmetics International
(2019)
Source URL:
First approved in 2011
Source:
21 CFR 352
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT04677712: Phase 4 Interventional Completed Edematous Fibrosclerotic Panniculopathy (EFP)
(2020)
Source URL:
First approved in 2008
Source:
M032
Source URL:
Class:
PROTEIN
